Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
10.1186/s12967-015-0405-4
Saved in:
Main Authors: | Wong A.L.A., Lim J.S.J., Sinha A., Gopinathan A., Lim R., Tan C.-S., Soh T., Venkatesh S., Titin C., Sapari N.S., Lee S.-C., Yong W.-P., Tan D.S.P., Pang B., Wang T.-T., Zee Y.-K., Soong R., Trnkova Z., Lathia C., Thiery J.-P., Wilhelm S., Jeffers M., Goh B.-C. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
BioMed Central Ltd.
2018
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/144324 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
by: Yong, W.P., et al.
Published: (2014) -
Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors
by: Lim, J.S.J, et al.
Published: (2020) -
Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
by: Huynh, H, et al.
Published: (2020) -
Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin
by: Kesara Na-Bangchang, et al.
Published: (2018) -
Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine
by: K. Na-Bangchang, et al.
Published: (2018)